MPHOSPH6

M-phase phosphoprotein 6 · Q99547 · MPHOSPH6 on Sugi Atlas →

0 patent compounds predicted against MPHOSPH6, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MPHOSPH6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma PHASE2COMPLETED
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Green Tea Extract and Prostate Cancer PHASE2COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer PHASE2COMPLETED
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor PHASE2ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy PHASE2COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders nanWITHDRAWN
Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs nanCOMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
NK Cell Deregulation in HBV Patients nanACTIVE_NOT_RECRUITING
Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Disorder nanRECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
CML Pediatric ITK Response According to Molecular Identification at Diagnosis nanRECRUITING
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MPHOSPH6 binder may also engage these)

ProteinNameSimilarity
Q9D1Q1 0.999 Q9D1Q1 →
Q8K039 0.975 Q8K039 →
Q96AT1 0.973 Q96AT1 →
Q3MHJ0 0.972 Q3MHJ0 →
Q5ZJ97 0.972 Q5ZJ97 →
Q6PII3 0.971 Q6PII3 →
Q5RKH3 0.970 Q5RKH3 →
Q3TQI7 0.969 Q3TQI7 →
Q9DBF7 0.968 Q9DBF7 →
Q9NZ63 0.967 Q9NZ63 →
Q5PQS7 0.966 Q5PQS7 →
Q3U155 0.964 Q3U155 →
Q5RC87 0.964 Q5RC87 →
Q96EY4 0.964 Q96EY4 →
Q3T062 0.964 Q3T062 →
Q9NXE8 0.963 Q9NXE8 →
Q5M947 0.963 Q5M947 →
Q91WE2 0.963 Q91WE2 →
Q9Z315 0.962 Q9Z315 →
Q5ZIH9 0.962 Q5ZIH9 →
Q9GZU8 0.962 Q9GZU8 →
Q5XIW8 0.962 Q5XIW8 →
Q76MT4 0.961 Q76MT4 →
Q4ADK7 0.961 Q4ADK7 →
Q8HXY9 0.961 Q8HXY9 →
O43290 0.961 O43290 →
O88271 0.960 O88271 →
RRP15 RRP15-like protein 0.960 landscape →
Q5XHI2 0.958 Q5XHI2 →
Q9H8W3 0.958 Q9H8W3 →